Presentation at forthcoming European Congress of Radiology (March 1-5 2017)
Provided by University of Brescia.
Presentation Details
Presentation Title: CT texture analysis in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors: prediction of survival
Author Block: J. Cardinale, V. Bettoni, G. Agazzi, M. Ravanelli, E. Roca, D. Farina, A. Berruti, R. Maroldi; Brescia/IT
(The presenting author is underlined.)
Disclosure Block: J. Cardinale: None. V. Bettoni: None. G. Agazzi: None. M. Ravanelli: None. E. Roca: None. D. Farina: None. A. Berruti: None. R. Maroldi: None.
Session Number: SS 204
Topic: Chest
Session Title: Lung cancer: from diagnosis to prognosis
Session Date/Time: Wednesday Mar 1 2017, 10:30 – 12:00
Room: 06/O
Below is a view of your accepted abstract:
Purpose: To assess the predictive and prognostic value of pre-treatment CT texture features in lung adenocarcinoma treated with tyrosine kinase inhibitors (TKI).
Methods and Materials: Texture analysis was performed with a commercially available software (TexRAD Ltd, UK) on pre-treatment contrast-enhanced CT studies of 27 patients with metastatic lung adenocarcinoma treated by TKI. Texture features were quantified on a 5-mm thick central slice of the 
primary tumour and were correlated with progression-free and overall survival (PFS and OS) using uni- and multi-variable analysis.
Results: Mean PFS and OS were 77.4±71 and 110±87 weeks, respectively. At multivariable analysis, kurtosis of 3-mm texture was independently correlated with PFS, tumours with high kurtosis (>0.98) had a 11.4 relative risk of progression compared with tumours with low kurtosis (p<0.0001); kurtosis on unfiltered images was correlated with OS, tumours with high kurtosis (>1.74) had a 10.3 relative risk of death compared with tumours with low kurtosis (p 0.0006). Among clinical variables, only age<60 years correlated with shorter PFS (relative risk 4.1, p0.02).
Conclusion: Texture features, in particular kurtosis, are strongly associated with PFS and OS in lung adenocarcinoma treated with TKI.
Link to ECR presentation page here